1023 - Suppressed Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide vs. Dolutegravir/Lamivudine: Virologic Failure and Durability

Presenting Author(s)

• 

  Gerald Pierone, Jr., MD (he/him/his)

  Research Officer
  Whole Family Health Center
  Vero Beach, FL, United States

  Slides

Co-Author(s)

• 

  Jennifer S. Fusco, BS

  Chief Science Officer
  Epividian, Inc.
  Durham, North Carolina, United States
• LB

  Laurence Brunet, PhD

  Director of Epidemiology
  Epividian, Inc.
  Durham, North Carolina, United States
• 

  Michael Sension, MD (he/him/his)

  Medical Director
  CAN Community Health
  Fort Lauderdale, Florida, United States
• 

  Megan Dunbar, PhD (she/her/hers)

  Senior Director, Global Medical Affairs
  Gilead Sciences
  Forest City, California, United States
• JG

  Joshua Gruber, PhD

  Gilead Sciences
  Forest City, California, United States
• DD

  Douglas Dieterich, MD

  Mount Sinai Healthcare System
  New York, New York, United States
• GF

  Gregory P. Fusco, MD, MPH

  Chief Executive Officer & Chief Medical Officer
  Epividian, Inc.
  Durham, North Carolina, United States